

## Neo-kyotorphin (Thr-Ser-Lys-Tyr-Arg), a new analgesic peptide

Yoshiaki Kiso, Kouki Kitagawa, Nobuyuki Kawai, Tadashi Akita, Hiroshi Takagi<sup>+</sup>, Hiroo Amano<sup>+</sup> and Kiyoshi Fukui\*

*Faculty of Pharmaceutical Sciences, University of Tokushima, Tokushima 770, <sup>+</sup>Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto 606 and \*Department of Pharmacology, Kagawa Medical School, Miki-cho, Kida-gun, Kagawa-ken 761-07, Japan*

Received 17 March 1983

The amino acid sequence of a newly isolated pentapeptide, neo-kyotorphin from bovine brain was synthetically verified to be Thr-Ser-Lys-Tyr-Arg corresponding to the C-terminal portion of hemoglobin  $\alpha$ -chain. The synthetic neo-kyotorphin showed the dose-dependent analgesia in mice which was approximately equal to that of Leu-enkephalin.

*Neo-kyotorphin      Bovine brain      Peptide synthesis      Analgesia      Kyotorphin      Hemoglobin*

### 1. INTRODUCTION

An analgesic dipeptide, kyotorphin (Tyr-Arg), from bovine brain was isolated and identified in [1,2]. During the course of kyotorphin isolation, a peptide-like substance, which elicited contraction in the guinea pig ileum, was detected in the methanol-soluble fraction. This peptide-like substance termed KT-2 has been isolated and the amino acid sequence proposed. However, further studies suggested that KT-2 contained a peptide and trace of histamine [3]. Therefore, we synthesized the pentapeptide corresponding to the proposed amino acid sequence for chemical and pharmacological characterization, and found that the synthetic pentapeptide was identical to the natural compound and did not induce contraction in the guinea pig ileum. Here, we show that the amino acid sequence of this newly isolated peptide (neo-kyotorphin) has been synthetically verified to be Thr-Ser-Lys-Tyr-Arg, corresponding to the

C-terminal portion of hemoglobin  $\alpha$ -chain. Synthetic neo-kyotorphin exhibited an analgesic effect but no inhibitory effect on the electrically evoked contraction of guinea pig ileum. The hemoglobin C-terminal pentapeptide exhibits analgesic activity.

### 2. EXPERIMENTAL

#### 2.1. Synthesis of peptides

The synthetic scheme is outlined in fig.1. Thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F-254 precoated plates (0.25 mm) in the solvent system; chloroform:methanol:water (8:3:1, by vol.), lower layer ( $R_f^1$ ). High-performance thin-layer chromatography (HPTLC) on cellulose plate (10 × 20 cm, 0.1 mm thick) was carried out in the solvent system; *n*-butanol:pyridine:acetic acid:water (15:10:3:12, by vol.) ( $R_f^2$ ). High-voltage paper electrophoresis (HVPE) was performed on Toyo no.51 filter paper at 50 V/cm for 90 min in a buffer (pH 3.6); pyridine:acetic acid:water (1:10:89, by vol.). To determine the relative mobility ( $R_m$ ) of each spot, arginine was used as a standard. Reverse-phase

*Abbreviations:* Z, benzyloxycarbonyl; Z(OMe), *p*-methoxybenzyloxycarbonyl; TFA, trifluoroacetic acid; Tos, *p*-toluenesulphonyl






Fig.2. High-voltage paper electrophoresis: (A) natural neo-kyotorphin; (B) natural and synthetic neo-kyotorphin (A + C); (C) synthetic neo-kyotorphin; (D) arginine as a standard.

by amino acid analyses, elemental analysis, HPTLC, HVPE, and HPLC, and was indicated to be the desired homogeneous peptide.

Synthetic pentapeptide was identical to the natural one on three different chromatographic systems; i.e., HPTLC ( $R_f^2 = 0.43$ ), HVPE ( $R_m = 0.91$ ) (fig.2) and HPLC (11 min). These verified that the structure of this peptide named neo-kyotorphin was Thr-Ser-Lys-Tyr-Arg.

Synthetic neo-kyotorphin exhibited no contracting effect on the isolated guinea pig ileum in a dose of  $2 \times 10^{-7}$  M. The electrophoretogram of KT-2 was extracted with 0.5 M acetic acid in the position in which  $R_m$  was identical to that of the authentic histamine. The extracted material induced contraction in the isolated guinea pig ileum, and diphenhydramine pretreatment inhibited this effect. Thus, it became clear that KT-2 contained both neo-kyotorphin and a trace of histamine.

Synthetic neo-kyotorphin exhibited a dose-dependent analgesic effect after intracisternal injection in mice. The  $ED_{50}$  value was 195 nmol/mouse. Analgesic activity of neo-kyotorphin is 5.6-times lower than that of kyotorphin ( $ED_{50} = 34.7$  nmol/mouse), and approximately equal to that of Leu-enkephalin ( $ED_{50} = 233$  nmol/mouse) [2,4,8]. However, synthetic neo-kyotorphin had no inhibitory effect on the electrically evoked contraction of the isolated guinea pig ileum in a dose of  $1.3 \times 10^{-4}$  M.

The peptide bond between Lys<sup>3</sup> and Tyr<sup>4</sup> in neo-kyotorphin could be cleaved by trypsin-like peptidase in the brain and Tyr-Arg (kyotorphin) was released from neo-kyotorphin [3]. Thr-Ser-Lys-NH<sub>2</sub> corresponding to the N-terminal portion of neo-kyotorphin (scheme 1) had been isolated

Scheme 1

	137	141	hemoglobin
-----	Val-Leu-Thr-Ser-Lys-Tyr-Arg		$\alpha$ -chain
	Thr-Ser-Lys-Tyr-Arg		neo-kyotorphin
		Tyr-Arg	kyotorphin
	Thr-Ser-Lys-NH <sub>2</sub>		antireproductive peptide

Amino acid sequences of neo-kyotorphin and related peptides

from the bovine pineal glands and shown to have antagonistic activity [9]. Moreover, the amino acid sequence of neo-kyotorphin is identical to that of the C-terminal portion of human and bovine hemoglobin  $\alpha$ -chain [10,11]. The hemoglobin C-terminal peptides exhibit biological activities, but the relationships between these peptides remain to be clarified.

#### ACKNOWLEDGEMENTS

The authors express their gratitude to Professors Haruaki Yajima, Yukio Ishida and Kyoza Hayashi for the encouragement during the course of this investigation. Thanks are also extended to Dr Nobutaka Fujii for amino acid analysis of an enzymatic hydrolysate and Dr Hideki Moritoki for helpful discussion.

#### REFERENCES

- [1] Takagi, H., Shiomi, H., Ueda, H. and Amano, H. (1979) *Nature* 282, 410-412.
- [2] Shiomi, H., Ueda, H. and Takagi, H. (1981) *Neuropharmacology* 20, 633-638.
- [3] Takagi, H., Shiomi, H., Fukui, K., Hayashi, K., Kiso, Y. and Kitagawa, K. (1982) *Life Sci.* 31, 1733-1736.
- [4] Ueda, H., Amano, H., Shiomi, H. and Takagi, H. (1979) *Eur. J. Pharmacol.* 56, 265-268.
- [5] Segawa, T., Hosokawa, K., Kitagawa, K. and Yajima, H. (1977) *J. Pharm. Pharmacol.* 29, 57-58.
- [6] Kosterlitz, H.W. and Watt, A.J. (1968) *Brit. J. Pharmacol. Chemother.* 33, 266-276.
- [7] Kiso, Y., Satomi, M., Ukawa, K. and Akita, T. (1980) *J. Chem. Soc. Chem. Commun.* 1063-1064.
- [8] Takagi, H., Shiomi, H., Ueda, H. and Amano, H. (1979) *Eur. J. Pharmacol.* 55, 109-111.

- [9] Orts, R.J., Liao, T., Sartin, J.L. and Bruot, B. (1978) *The Physiologist* 21, 87.
- [10] Hill, R.J. and Konigsberg, W. (1962) *J. Biol. Chem.* 238, 3151-3156.
- [11] Schroeder, W.A., Shelton, J.R., Shelton, J.B., Robberson, B. and Babin, D.R. (1967) *Arch. Biochem. Biophys.* 120, 1-14.